Related Experiment Video
Updated: May 8, 2026

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
Published on: October 6, 2022
Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV/AIDS
J L Casado1, I Corral, J García
1Department of Infectious Diseases, Ramón y Cajal Hospital, 28034, Madrid, Spain, jcasado.hrc@gmail.com.
Abstract:
To evaluate the situation and perspectives of progressive multifocal leukoencephalopathy (PML) in human immunodeficiency virus (HIV)-infected patients, we investigated changes in the incidence, causes, and long-term outcome of this disease in 72 acquired immunodeficiency syndrome (AIDS) patients who were diagnosed with PML from 1996 to 2011. Patients were classified according to the date of diagnosis in the first (1996-2000, n = 35), second (2001-2006, n = 26), and recent or third highly active antiretroviral therapy (HAART) period (2007-2011, n = 11). Overall, the incidence of PML decreased from 14.8 cases/1,000 patients/year in 1996 to 2.6 in 2005 and 0.8 in 2011, and nearly two-thirds of recent cases (64 %) were observed in HIV patients not attending clinical visits. The baseline median CD4+ count was higher in recently PML-diagnosed patients (77 vs. 86 vs. 101 cells/mm(3); p < 0.01), and this fact was associated with a cerebrospinal fluid (CSF) inflammatory profile (from 11 to 31 to 55 %, p = 0.007) and with a significantly longer survival (attributable death, 54 vs. 35 vs. 36 %, respectively, p < 0.01). Thus, the overall 1-year and 3-year survival rates were 55 and 50 %, respectively, increasing to 79 % at 1 year for patients with CD4+ count above 100 cells/mm(3) at diagnosis. In a Cox regression analysis, an older age (hazard ratio, HR 0.76), a baseline CD4+ count above 100 cells/mm(3) (HR 0.33), and a CSF inflammatory profile (HR 0.12) were significantly associated with a longer survival. The clinical presentation and outcome of PML in AIDS patients continue to change dramatically. Now, a declining incidence and long-term survival is observed.
Insights
Progressive multifocal leukoencephalopathy (PML) incidence in human immunodeficiency virus (HIV)-infected patients has declined significantly. Improved survival rates are linked to higher CD4+ counts and cerebrospinal fluid (CSF) inflammation.
Area of Science:
- Neuroscience
- Infectious Diseases
- Immunology
Background:
- Progressive multifocal leukoencephalopathy (PML) is a rare, opportunistic infection affecting the central nervous system.
- In human immunodeficiency virus (HIV)-infected individuals, PML was historically associated with severe immunosuppression and poor prognosis.
- The advent of highly active antiretroviral therapy (HAART) has altered the epidemiology and clinical course of many opportunistic infections in HIV/acquired immunodeficiency syndrome (AIDS) patients.
Purpose of the Study:
- To evaluate the changing incidence, causes, and long-term outcomes of PML in HIV-infected patients.
- To analyze trends in PML diagnosis and survival across different periods of HAART availability.
- To identify factors associated with improved survival in HIV-associated PML.
Main Methods:
- Retrospective analysis of 72 acquired immunodeficiency syndrome (AIDS) patients diagnosed with PML between 1996 and 2011.
- Classification of patients into three diagnostic periods: 1996-2000, 2001-2006, and 2007-2011 (HAART era).
- Evaluation of incidence rates, CD4+ T-cell counts, cerebrospinal fluid (CSF) profiles, and survival data using statistical analyses, including Cox regression.
Main Results:
- Overall PML incidence decreased significantly from 14.8 cases/1,000 patient-years in 1996 to 0.8 in 2011.
- A higher proportion of recent PML cases (64%) occurred in HIV patients not attending clinical visits.
- Patients diagnosed more recently exhibited higher median CD4+ counts, increased CSF inflammatory profiles, and significantly longer survival rates (1-year survival up to 79% for CD4+ >100 cells/mm³).
Conclusions:
- The incidence of PML in HIV-infected patients has dramatically declined.
- Improved long-term survival in HIV-associated PML is associated with higher baseline CD4+ counts and CSF inflammatory markers.
- Despite declining incidence, PML remains a significant concern, particularly in patients with poor clinical engagement.
Related Concept Videos
Retrovirus Life Cycles
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Encephalitis ll: Pathophysiology
Cytomegalovirus Disease
Encephalitis l: Introduction
Sexually Transmitted Infections
